NASDAQ:TGTX • US88322Q1085
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for TG THERAPEUTICS INC (TGTX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-02 | JP Morgan | Maintains | Overweight -> Overweight |
| 2026-01-15 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-11-03 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-09-17 | B. Riley Securities | Maintains | Buy -> Buy |
| 2025-03-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-25 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-11-05 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2024-11-05 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-10-29 | TD Cowen | Initiate | Buy |
| 2024-09-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-07 | B. Riley Securities | Maintains | Buy -> Buy |
| 2024-08-07 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2024-08-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-02 | Ladenburg Thalmann | Maintains | Buy -> Buy |
| 2024-05-02 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-04-18 | Ladenburg Thalmann | Reiterate | Buy -> Buy |
| 2024-04-18 | JP Morgan | Reiterate | Overweight -> Overweight |
| 2024-04-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-02-29 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2024-02-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-02-05 | B. Riley Securities | Maintains | Buy -> Buy |
| 2024-01-11 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-01 | JP Morgan | Maintains | Overweight -> Overweight |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 233.662M 8,290.02% | 329.004M 40.80% | 616.287M 87.32% | 918.76M 49.08% | 1.164B 26.69% | 1.515B 30.15% | 1.762B 16.30% | 1.978B 12.26% | 2.231B 12.79% | 2.444B 9.55% | 2.652B 8.51% | |
| EBITDA YoY % growth | 20.844M 109.56% | 41.997M 101.48% | 123.383M 193.79% | 256.29M 107.72% | 427.07M 66.64% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | 20.633M 109.45% | 41.929M 103.21% | 123.324M 194.13% | 290.45M 135.52% | 457.01M 57.35% | 623.17M 36.36% | 768.95M 23.39% | 881.13M 14.59% | 1.068B 21.21% | 1.191B 11.52% | 1.313B 10.24% | |
| Operating Margin | 8.83% | 12.74% | 20.01% | 31.61% | 39.26% | 41.13% | 43.64% | 44.55% | 47.87% | 48.73% | 49.51% | |
| EPS YoY % growth | 0.01 100.68% | 0.14 1,300.00% | 0.50 257.14% | 1.48 195.80% | 2.28 54.48% | 2.76 20.98% | 3.76 35.98% | 4.19 11.40% | 5.76 37.64% | N/A | N/A |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | 0.30 915.48% | 0.36 111.30% | 0.36 125.04% | 0.48 243.52% |
| Revenue Q2Q % growth | 203.04M 68.00% | 219.22M 55.31% | 236.06M 45.98% | 261.92M 36.01% |
| EBITDA Q2Q % growth | 59.668M 591.40% | 69.107M 98.22% | 59.715M 103.09% | 86.7M 71.50% |
| EBIT Q2Q % growth | 58.533M 578.88% | 67.428M 93.52% | 68.531M 133.38% | 94.248M 86.65% |
All data in USD
15 analysts have analysed TGTX and the average price target is 45.05 USD. This implies a price increase of 27.51% is expected in the next year compared to the current price of 35.33.
TG THERAPEUTICS INC (TGTX) will report earnings on 2026-05-11.
The consensus EPS estimate for the next earnings of TG THERAPEUTICS INC (TGTX) is 0.3 USD and the consensus revenue estimate is 203.04M USD.
The number of analysts covering TG THERAPEUTICS INC (TGTX) is 15.